CURRENT TARGET OF ANTIHYPERTENSIVE THERAPY. DATA FROM CLINICAL TRIALS. PART 2
Arterial hypertension (HT) takes leading position in the structure of morbidity and mortality among the cardiovascular diseases in the economically developed and developing countries of the world. Despite progress in treatment of this disease, a number of people with uncontrolled or resistant HT inc...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-12-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/563 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227883112824832 |
|---|---|
| author | V. V. Popov N. A. Bulanov G. G. Ivanov |
| author_facet | V. V. Popov N. A. Bulanov G. G. Ivanov |
| author_sort | V. V. Popov |
| collection | DOAJ |
| description | Arterial hypertension (HT) takes leading position in the structure of morbidity and mortality among the cardiovascular diseases in the economically developed and developing countries of the world. Despite progress in treatment of this disease, a number of people with uncontrolled or resistant HT increases. There is a problem of inefficiency of therapy or lack of patients' adherence to treatment. Therefore, search for new approaches to treatment of HT continues. Current most effective agents for blood pressure control, and possible future antihypertensive agents, are related to groups of agents, which inhibit renin–angiotensin–aldosterone system (RAAS). Novel targets for antihypertensive therapy could include the angiotensin II type 2 and type 1 receptor , neutral endopeptidase, aldosterone synthase, renalase, endothelin receptors, (pro)renin receptors, vaccine against RAAS components. Development of novel agents and approaches to HT therapy is discussed. |
| format | Article |
| id | doaj-art-9cb34140998440a88a82729ae85cc6f0 |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2015-12-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-9cb34140998440a88a82729ae85cc6f02025-08-23T10:00:20ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-12-018222623210.20996/1819-6446-2012-8-2-226-232563CURRENT TARGET OF ANTIHYPERTENSIVE THERAPY. DATA FROM CLINICAL TRIALS. PART 2V. V. Popov0N. A. Bulanov1G. G. Ivanov2Research Clinical Center of JSC "Russian Railways"I.M. Setchenov First Moscow State Medical UniversityI.M. Setchenov First Moscow State Medical UniversityArterial hypertension (HT) takes leading position in the structure of morbidity and mortality among the cardiovascular diseases in the economically developed and developing countries of the world. Despite progress in treatment of this disease, a number of people with uncontrolled or resistant HT increases. There is a problem of inefficiency of therapy or lack of patients' adherence to treatment. Therefore, search for new approaches to treatment of HT continues. Current most effective agents for blood pressure control, and possible future antihypertensive agents, are related to groups of agents, which inhibit renin–angiotensin–aldosterone system (RAAS). Novel targets for antihypertensive therapy could include the angiotensin II type 2 and type 1 receptor , neutral endopeptidase, aldosterone synthase, renalase, endothelin receptors, (pro)renin receptors, vaccine against RAAS components. Development of novel agents and approaches to HT therapy is discussed.https://www.rpcardio.online/jour/article/view/563arterial hypertensionantihypertensive drugspharmacological targetsclinical trials |
| spellingShingle | V. V. Popov N. A. Bulanov G. G. Ivanov CURRENT TARGET OF ANTIHYPERTENSIVE THERAPY. DATA FROM CLINICAL TRIALS. PART 2 Рациональная фармакотерапия в кардиологии arterial hypertension antihypertensive drugs pharmacological targets clinical trials |
| title | CURRENT TARGET OF ANTIHYPERTENSIVE THERAPY. DATA FROM CLINICAL TRIALS. PART 2 |
| title_full | CURRENT TARGET OF ANTIHYPERTENSIVE THERAPY. DATA FROM CLINICAL TRIALS. PART 2 |
| title_fullStr | CURRENT TARGET OF ANTIHYPERTENSIVE THERAPY. DATA FROM CLINICAL TRIALS. PART 2 |
| title_full_unstemmed | CURRENT TARGET OF ANTIHYPERTENSIVE THERAPY. DATA FROM CLINICAL TRIALS. PART 2 |
| title_short | CURRENT TARGET OF ANTIHYPERTENSIVE THERAPY. DATA FROM CLINICAL TRIALS. PART 2 |
| title_sort | current target of antihypertensive therapy data from clinical trials part 2 |
| topic | arterial hypertension antihypertensive drugs pharmacological targets clinical trials |
| url | https://www.rpcardio.online/jour/article/view/563 |
| work_keys_str_mv | AT vvpopov currenttargetofantihypertensivetherapydatafromclinicaltrialspart2 AT nabulanov currenttargetofantihypertensivetherapydatafromclinicaltrialspart2 AT ggivanov currenttargetofantihypertensivetherapydatafromclinicaltrialspart2 |